Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company, was acquired by Pfizer in August 2022. GBT focused on developing treatments for sickle cell disease (SCD), particularly its flagship drug, Oxbryta (voxelotor), which was the first FDA-approved medication to directly target the root cause of red blood cell sickling.